Attendee search 

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world.

Focuses on developing novel small molecule drug

IHM-GBA is an investor and an innovation center in Guangzhou, China. The firm is looking to invest in the medical device sector. The firm is highly focusing on investment and cooperation in high-performance innovative medical device companies. The firm also helps companies to enter the Chinese market.

Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies to patients with cancer, autoimmune and infectious diseases in China and around the world.

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.

MNC

Healthcare Consulting and Investment

Focused in genitourinary（GU）/women health field with 2 global assets for bladder cancer and pre-cervical cancer treatment in phase 3 stages，looking for in/out-licensing partnership in GU/women health area

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.

We are a leading CRO biotech company. We focus on antibody development.